Enhanced liver fibrosis score predicts transplant‐free survival in primary sclerosing cholangitis

Mette Vesterhus(Oslo University Hospital), Johannes R. Hov(Oslo University Hospital), Anders Holm(Oslo University Hospital), Erik Schrumpf(Oslo University Hospital), Ståle Nygård(Oslo University Hospital), Kristin Godang(Oslo University Hospital), Ina Marie Andersen(Oslo University Hospital), Sigrid Næss(Oslo University Hospital), Douglas Thorburn(Royal Free London NHS Foundation Trust), Francesca Saffioti(Royal Free London NHS Foundation Trust), Morten Vatn(Oslo University Hospital), Odd Helge Gilja(Oslo University Hospital), Fridtjof Lund‐Johansen(Oslo University Hospital), Trygve Syversveen(Oslo University Hospital), Knut Brabrand(Oslo University Hospital), Albert Parés(Oslo University Hospital), Cyriel Y. Ponsioen(Oslo University Hospital), Massimo Pinzani(Royal Free London NHS Foundation Trust), Martti Färkkilâ(Oslo University Hospital), Bjørn Moum(Oslo University Hospital), Thor Ueland(Oslo University Hospital), Helge Røsjø(Oslo University Hospital), William Rosenberg(Royal Free London NHS Foundation Trust), Kirsten Muri Boberg(Oslo University Hospital), Tom H. Karlsen(Oslo University Hospital)
Hepatology
April 2, 2015
Cited by 132Open Access
Full Text

Abstract

UNLABELLED: There is a need to determine biomarkers reflecting disease activity and prognosis in primary sclerosing cholangitis (PSC). We evaluated the prognostic utility of the enhanced liver fibrosis (ELF) score in Norwegian PSC patients. Serum samples were available from 305 well-characterized large-duct PSC patients, 96 ulcerative colitis patients, and 100 healthy controls. The PSC patients constituted a derivation panel (recruited 1992-2006 [n = 167]; median age 41 years, 74% male) and a validation panel (recruited 2008-2012 [n = 138]; median age 40 years, 78% male). We used commercial kits to analyze serum levels of hyaluronic acid, tissue inhibitor of metalloproteinases-1, and propeptide of type III procollagen and calculated ELF scores by the previously published algorithm. Results were also validated by analysis of ELF tests using the ADVIA Centaur XP system and its commercially available reagents. We found that PSC patients stratified by ELF score tertiles exhibited significantly different transplant-free survival in both panels (P < 0.001), with higher scores associated with shorter survival, which was confirmed in the validation panel stratified by ELF test tertiles (P = 0.003). The ELF test distinguished between mild and severe disease defined by clinical outcome (transplantation or death) with an area under the curve of 0.81 (95% confidence interval [CI] 0.73-0.87) and optimal cutoff of 10.6 (sensitivity 70.2%, specificity 79.1%). In multivariate Cox regression analysis in both panels, ELF score (hazard ratio = 1.9, 95% CI 1.4-2.5, and 1.5, 95% CI 1.1-2.1, respectively) was associated with transplant-free survival independently of the Mayo risk score (hazard ratio = 1.3, 95% CI 1.1-1.6, and 1.6, 95% CI 1.2-2.1, respectively). The ELF test correlated with ultrasound elastography in separate assessments. CONCLUSION: The ELF score is a potent prognostic marker in PSC, independent of the Mayo risk score.


Related Papers

No related papers found

Powered by citation graph analysis